Journal of Affective Disorders
Volume 84, Issue 1 , Pages 1-13 , January 2005

Evidence of cost-effective treatments for depression: a systematic review

  • Barbara Barrett

      Affiliations

    • Centre for the Economics of Mental Health, Institute of Psychiatry, Box P024, SE5 8AF, London, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7848 5091; fax: +44 20 7701 7600.
    • ,
  • Sarah Byford

      Affiliations

    • Centre for the Economics of Mental Health, Institute of Psychiatry, Box P024, SE5 8AF, London, UK
    • ,
  • Martin Knapp

      Affiliations

    • Centre for the Economics of Mental Health, Institute of Psychiatry, Box P024, SE5 8AF, London, UK
    • LSE Health and Social Care, London School of Economics, London, UK

Received 25 May 2004 ,Revised 5 October 2004 ,Accepted 5 October 2004.

References 

  1. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol. Bull. 1995;31:249–258
  2. Boath E, Major K, Cox J. When the cradle falls: II. The cost-effectiveness of treating postnatal depression in a psychiatric day hospital compared with routine primary care. J. Affect. Disord. 2003;74:159–166
  3. Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur. Psychiatr. 2000;15:378–387
  4. Bower P, Byford S, Sibbald B, Ward E, King M, Lloyd M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression: II. Cost-effectiveness. BMJ. 2000;321:1389–1392
  5. Bower P, Byford S, Barber J, Beecham J, Simpson S, Friedli K, et al. Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. BMJ. 2003;326:1247–1250
  6. Briggs A. Economic evaluation and clinical trials: size matters. BMJ. 2003;321:1362–1363
  7. Brown MCJ, Van Loon JMT, Guest JF. Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in Austria. Eur. J. Psychiatry. 1999;14:230–244
  8. Brown MCJ, Van Loon JMT, Guest JF. Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France. Eur. J. Psychiatry. 2000;14:15–25
  9. Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J. Affect. Disord. 2002;68:317–330
  10. Byford S, Bower P. Cost-effectiveness of cognitive-behavioral therapy for depression: current evidence and future research priorities. Expert Rev. Pharmacoecon. Outcomes Res. 2002;2:457–464
  11. Byford S, McCrone P, Barrett B. Developments in the quantity and quality of economic evaluations in mental health. Curr. Opin. Psychiatry. 2003;16:703–707
  12. Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Manag. Care Interface. 2003;Suppl. B:16–21
  13. Casciano J, Arikian S, Tarride JE, Doyle JJ, Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Epidemiol. Psichiatr. Soc. 1999;8:220–231
  14. Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: a multinational study. Int. J. Clin. Pract. 2001;55:292–299
  15. CCOHTA . Selective Serotonin Reuptake Inhibitors (SSRIs) for Major Depression: Part II. The Cost-effectiveness of SSRIs in Treatment of Depression. Ottowa: Canadian Coordinating Office for Health Technology Assessment; 1997;
  16. Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health. 2001;4:16–31
  17. Drummond M, McGuire A. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001;
  18. Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin. Ther. 1995;17:136–153
  19. Evers SM, Van Wijk AS, Ament AJ. Economic evaluation of mental health care interventions. A Review. Health Econ. 1997;6:161–177
  20. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 2004;13:405–415
  21. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J. Affect. Disord. 1996;38:97–111
  22. François C, Toumi M, Aakhusz A-M, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor: comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur. J. Health Econ. 2003;4:12–19
  23. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. PharmacoEconomics. 2000;18:143–148
  24. Friedli K, King MB, Lloyd M. The economics of employing a counsellor in general practice: analysis of data from a randomised controlled trial. Br. J. Gen. Pract. 2000;50:273–283
  25. Gill, D., Hatcher, J., 2002. Antidepressants for depression in medical illness. The Cochrane Library, Issue 2, 2002. Update Software, Oxford.
  26. Goldberg D, Jackson G, Gater R, Campbell M, Jennett N. The treatment of common mental disorders by a community team based in primary care: a cost-effectiveness study. Psychol. Med. 1996;26:487–492
  27. Gournay K, Brooking J. The community psychiatric nurse in primary care: an economic analysis. J. Adv. Nurs. 1995;22:769–778
  28. Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch. Gen. Psychiatry. 1999;56:519–526
  29. Harvey I, Nelson S, Lyons R, Unwin C, Monaghan S, Peters T. A randomised controlled trial and economic evaluation of counselling in primary care. Br. J. Gen. Pract. 1998;48:1043–1048
  30. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics. 1994;5:249–268
  31. Hosak L, Tuma I, Hanus H, Straka L. Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. Acta Med. Hradec Kral. 2000;43:133–137
  32. Hylan TR, Buesching DP, Tollefson GD. Health economic evaluations of antidepressants: a review. Depress. Anxiety. 1998;7:53–64
  33. Jönsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br. J. Psychiatry. 1995;164:665–673
  34. Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol. Assess. (Winch., Engl.). 2002;6:1–89
  35. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin. Trials. 1995;16:17–40
  36. Katon W, Russo J, Von Korff M, Lin E, Simon G, Bush T, et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. J. Gen. Intern. Med. 2002;17:741–748
  37. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int. Clin. Psychopharmacol. 1995;10(Suppl. 1):41–48
  38. Knapp M. Hidden costs of mental illness. Br. J. Psychiatry. 2003;183:477–478
  39. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch. Gen. Psychiatry. 1998;55:645–651
  40. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. J. Affect. Disord. 1994;31:1–18
  41. Leff J, Vearnals S, Brewin CR, Wolff G, Alexander B, Asen E, et al. The London depression intervention trial. Randomised controlled trial of antidepressants: V. Couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. Br. J. Psychiatry. 2000;177:95–100
  42. Liu CF, Hedrick SC, Chaney EF, Heagerty P, Felker B, Hasenberg N, et al. Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatr. Serv. 2003;54:698–704
  43. Markle-Reid M, Browne G, Roberts J, Gafni A, Byrne C. The 2-year costs and effects of a public health nursing case management intervention on mood-disordered single parents on social assistance. J. Eval. Clin. Pract. 2002;8:45–59
  44. Miller P, Chilvers C, Dewey M, Fielding K, Gretton V, Palmer B, et al. Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care: economic analysis. Int. J. Technol. Assess. Health Care. 2003;19:80–90
  45. Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A. Costs and effectiveness of community postnatal support workers: randomised controlled trial. BMJ. 2000;321:593–598
  46. Murray CJL, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global burden of disease study. Lancet. 1997;349:1347–1352
  47. Mynors-Wallis L, Davies I, Gray A, Barbour F, Gath D. A randomised controlled trial and cost analysis of problem-solving treatment for emotional disorders given by community nurses in primary care. Br. J. Psychiatry. 1997;170:113–119
  48. Nuijten MJ, Hardens M, Souetre E. A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. PharmacoEconomics. 1995;8:159–168
  49. Nuijten M, Hadjadjeba L, Evans C, van den BJ. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. PharmacoEconomics. 1998;14:433–445
  50. Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Lancet. 2003;361:33–39
  51. Prodigy, 2004. Depression Clinical Guidelines. http://www.prodigy.nhs.uk, accessed on 30-3-2004.
  52. Pyne JM, Rost KM, Zhang M, Williams DK, Smith J, Fortney J. Cost-effectiveness of a primary care depression intervention. J. Gen. Intern. Med. 2003;18:432–441
  53. Pyne JM, Smith J, Fortney J, Zhang M, Williams DK, Rost K. Cost-effectiveness of a primary care intervention for depressed females. J. Affect. Disord. 2003;74:23–32
  54. Revicki D, Brown RE, Palmer W, Bakish D, Rosser WW, Anton SF, et al. Modelling the cost-effectiveness of antidepressant treatment in depression. PharmacoEconomics. 1995;8:524–540
  55. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry. 1997;58:47–58
  56. Richards A, Barkham M, Cahill J, Richards D, Williams C, Heywood P. PHASE: a randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. Br. J. Gen. Pract. 2003;53:764–770
  57. Rosenbaum JF, Hylan TR. Costs of depressive disorders: a review. In:  Maj M,  Sartorius N editor. Depressive Disorders. Second edn.. Chichester: Wiley; 2002;
  58. Sacristan JA, Gilaberte I, Boto B, Buesching DP, Obenchain RL, Demitrack M, et al. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. Int. Clin. Psychopharmacol. 2000;15:107–113
  59. Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA. 2001;286:1325–1330
  60. Scott AI, Freeman CP. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. BMJ. 1992;304:883–887
  61. Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression: cost-effectiveness study. Br. J. Psychiatry. 2003;182:221–227
  62. Simon GE, Von Korff M, Heiligenstein J, Revicki D, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA. 1996;275:1897–1899
  63. Simon GE, Heiligenstein J, Revicki D, Von Korff M, Katon W, Ludman E, et al. Long-term outcomes of initial antidepressant drug choice in a “real world” randomised trial. Arch. Fam. Med. 1999;8:319–325
  64. Simon GE, Revicki D, Heiligenstein J, Grothaus L, Von Korff M, Katon WJ, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen. Hosp. Psych. 2000;22:153–162
  65. Simon GE, Von Korff M, Rutter C, Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ. 2000;320:550–554
  66. Simon GE, Katon WJ, Von Korff M, Unutzer J, Lin EH, Walker EA, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am. J. Psychiatry. 2001;158:1638–1644
  67. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CP. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch. Gen. Psychiatry. 2001;58:181–187
  68. Simon GE, Von Korff M, Ludman EJ, Katon WJ, Rutter C, Unutzer J, et al. Cost-effectiveness of a program to prevent depression relapse in primary care. Med. Care. 2002;40:941–950
  69. Simpson S, Corney R, Fitzgerald P, Beecham J. A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression. Psychol. Med. 2003;33:229–239
  70. Stewart A. Anti-depressant pharmacotherapy: cost comparison of SSRIs and TCAs. Br. J. Med. Econ. 1994;7:69–79
  71. Stewart A. Revisiting the relative cost-effectiveness of selective serotonin re-uptake inhibitors and tricyclic antidepressants: what price inflation and subtherapeutic dosages?. Br. J. Med. Econ. 1996;10:203–216
  72. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br. J. Psychiatry. 2003;183:514–519
  73. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann. Intern. Med. 2001;134:345–360
  74. Von Korff M, Katon W, Bush T, Lin EH, Simon GE, Saunders K, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom. Med. 1998;60:143–149
  75. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br. J. Psychiatry. 1997;170:257–263

PII: S0165-0327(04)00365-9

doi: 10.1016/j.jad.2004.10.003

Journal of Affective Disorders
Volume 84, Issue 1 , Pages 1-13 , January 2005

Article Tools

* Image Usage & Resolution